Cholesterol guidelines update: More aggressive therapy for higher-risk patients

Julie C. Huang, MD
Preventive Cardiology Section, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Byron J. Hoogwerf, MD
Preventive Cardiology Section, Department of Cardiovascular Medicine; Department of Endocrinology, Diabetes, and Metabolism, The Cleveland Clinic Foundation

Address: Julie Huang, MD, Section of Preventive Cardiology, C51, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; email huangj1@ccf.org

Dr. Hoogwerf has indicated that he has received grant or research support from the Amylin and Eli Lilly corporations, serves as a consultant for the Astra Zeneca, Bayer, Eli Lilly, McNeil, Merck, Pfizer, Takeda, and Wyeth corporations, and is on the speaker’s bureaus of the Astra Zeneca, Aventis, Bristol Myers Squibb, Eli Lilly, King, Merck, Monarch, Novo Nordisk, Pfizer, Schering Plough, Takeda, and Wyeth corporations.

Julie C. Huang, MD
Preventive Cardiology Section, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Byron J. Hoogwerf, MD
Preventive Cardiology Section, Department of Cardiovascular Medicine; Department of Endocrinology, Diabetes, and Metabolism, The Cleveland Clinic Foundation

Address: Julie Huang, MD, Section of Preventive Cardiology, C51, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; email huangj1@ccf.org

Dr. Hoogwerf has indicated that he has received grant or research support from the Amylin and Eli Lilly corporations, serves as a consultant for the Astra Zeneca, Bayer, Eli Lilly, McNeil, Merck, Pfizer, Takeda, and Wyeth corporations, and is on the speaker’s bureaus of the Astra Zeneca, Aventis, Bristol Myers Squibb, Eli Lilly, King, Merck, Monarch, Novo Nordisk, Pfizer, Schering Plough, Takeda, and Wyeth corporations.

Julie C. Huang, MD
Preventive Cardiology Section, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Byron J. Hoogwerf, MD
Preventive Cardiology Section, Department of Cardiovascular Medicine; Department of Endocrinology, Diabetes, and Metabolism, The Cleveland Clinic Foundation

Address: Julie Huang, MD, Section of Preventive Cardiology, C51, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; email huangj1@ccf.org

Dr. Hoogwerf has indicated that he has received grant or research support from the Amylin and Eli Lilly corporations, serves as a consultant for the Astra Zeneca, Bayer, Eli Lilly, McNeil, Merck, Pfizer, Takeda, and Wyeth corporations, and is on the speaker’s bureaus of the Astra Zeneca, Aventis, Bristol Myers Squibb, Eli Lilly, King, Merck, Monarch, Novo Nordisk, Pfizer, Schering Plough, Takeda, and Wyeth corporations.